Payment overview · 2025
General Payments
$676.77
39 reported records · 16 companies
Healthcare provider profile · identity verified
Joel Adler, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TEANECK, NJ · NPI 1679655930
Verified facts
What the public records show
CMS Open Payments records show Joel Adler, MD received $676.77 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Farxiga, Gemtesa, Jardiance, Mounjaro, Rexulti, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 873 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $97.14 | 14.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.77 | 11.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.89 | 9.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $64.27 | 9.5% | 4 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $61.01 | 9.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.54 | 8.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.88 | 7.7% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $47.14 | 7.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.76 | 5.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.51 | 3.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.23 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.90 | 2.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.20 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.11 | 2.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.65 | 2.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.77 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $676.77 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $118.81 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $97.14 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.89 | 3 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $61.01 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $47.14 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.07 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.07 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $35.70 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $34.62 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 161 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 368 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
161 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
368 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
368 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
873 | 77 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1242 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1097 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 903 | 100 |
| Eliquis | Apixaban | 873 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 775 | 100 |
| Divalproex Sodium | Divalproex Sodium | 731 | 54 |
| Gabapentin | Gabapentin | 728 | 66 |
| Mirtazapine | Mirtazapine | 702 | 70 |
| Sertraline Hcl | Sertraline Hcl | 687 | 48 |
| Donepezil Hcl | Donepezil Hcl | 676 | 52 |
| Famotidine | Famotidine | 624 | 65 |
| Losartan Potassium | Losartan Potassium | 573 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 545 | 74 |
| Potassium Chloride | Potassium Chloride | 487 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 450 | 55 |
| Metformin Hcl | Metformin Hcl | 419 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 418 | 61 |
| Carvedilol | Carvedilol | 392 | 46 |
| Furosemide | Furosemide | 387 | 66 |
| Quetiapine Fumarate | Quetiapine Fumarate | 385 | 27 |
| Lorazepam | Lorazepam | 384 | 48 |
| Jardiance | Empagliflozin | 368 | 37 |
| Xarelto | Rivaroxaban | 361 | 25 |
| Memantine Hcl | Memantine Hcl | 355 | 29 |
| Prednisone | Prednisone | 337 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 290 | 36 |
| Trazodone Hcl | Trazodone Hcl | 276 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 260 | 39 |
| Montelukast Sodium | Montelukast Sodium | 259 | 23 |
| Myrbetriq | Mirabegron | 257 | 22 |
| Spironolactone | Spironolactone | 257 | 31 |
| Simvastatin | Simvastatin | 256 | 54 |
| Torsemide | Torsemide | 238 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 233 | 28 |
| Lisinopril | Lisinopril | 226 | 30 |
| Meloxicam | Meloxicam | 186 | 24 |
| Memantine Hcl Er | Memantine Hcl | 177 | suppressed |
| Alprazolam | Alprazolam | 171 | 34 |
| Farxiga | Dapagliflozin Propanediol | 161 | 38 |
| Midodrine Hcl | Midodrine Hcl | 156 | 21 |
| Baclofen | Baclofen | 142 | 18 |
| Clonazepam | Clonazepam | 136 | 22 |
| Tramadol Hcl | Tramadol Hcl | 135 | 47 |
| Finasteride | Finasteride | 132 | 24 |
| Celecoxib | Celecoxib | 126 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 123 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 122 | 46 |
| Omeprazole | Omeprazole | 118 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 11 |
| Buspirone Hcl | Buspirone Hcl | 112 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 105 | suppressed |
| Latanoprost | Latanoprost | 104 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 102 | suppressed |
| Levetiracetam | Levetiracetam | 96 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | suppressed |
| Atenolol | Atenolol | 88 | 13 |
| Clonidine Hcl | Clonidine Hcl | 88 | 14 |
| Folic Acid | Folic Acid | 83 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 82 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 82 | suppressed |
| Nystatin | Nystatin | 81 | 36 |
| Propranolol Hcl | Propranolol Hcl | 80 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 19 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 76 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 28 |
| Entresto | Sacubitril/Valsartan | 74 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | suppressed |
| Telmisartan | Telmisartan | 74 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 47 |
| Glimepiride | Glimepiride | 72 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 26 |
| Ranolazine Er | Ranolazine | 67 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 65 | 21 |
| Bupropion Xl | Bupropion Hcl | 62 | suppressed |
| Ezetimibe | Ezetimibe | 62 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 61 | 26 |
| Allopurinol | Allopurinol | 61 | 15 |
| Labetalol Hcl | Labetalol Hcl | 61 | suppressed |
| Lactulose | Lactulose | 60 | 20 |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 28 |
| Colchicine | Colchicine | 54 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 33 |
| Olanzapine | Olanzapine | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 14 |
| Risperidone | Risperidone | 46 | suppressed |
| Tradjenta | Linagliptin | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Valsartan | Valsartan | 46 | suppressed |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Nyamyc | Nystatin | 44 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Digoxin | Digoxin | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 13 |
| Pregabalin | Pregabalin | 42 | 13 |
| Anastrozole | Anastrozole | 40 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 40 | 13 |
| Januvia | Sitagliptin Phosphate | 38 | 11 |
| Rexulti | Brexpiprazole | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 11 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 34 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | suppressed |
| Dutasteride | Dutasteride | 28 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | 12 |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 14 |
| Ondansetron Odt | Ondansetron | 26 | 16 |
| Sodium Chloride | Sodium Chloride 0.45 % | 26 | 11 |
| Lacosamide | Lacosamide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Scopolamine | Scopolamine | 23 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 22 | 22 |
| Cephalexin | Cephalexin | 22 | 13 |
| Clonidine | Clonidine | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 13 |
| Belsomra | Suvorexant | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Pancreaze | Lipase/Protease/Amylase | 21 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 21 | suppressed |
| Austedo | Deutetrabenazine | 20 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | 15 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 20 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 12 |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Fingolimod | Fingolimod Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Exemestane | Exemestane | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Repaglinide | Repaglinide | 14 | suppressed |
| Rifampin | Rifampin | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Acetylcysteine | Acetylcysteine | 12 | suppressed |
| Austedo Xr | Deutetrabenazine | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $676.77 · 39 records | AstraZeneca Pharmaceuticals LP | AUSTEDO XR, Belbuca, CAPLYTA, Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, PAXLOVID, REXULTI, The Cologuard Plus Collection Kit, VYNDAQEL, WATCHMAN Access System, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error